Literature DB >> 33175610

Shortened derivatives from native antimicrobial peptide LyeTx I: In vitro and in vivo biological activity assessment.

Leonardo Lima Fuscaldi1, Joaquim Teixeira de Avelar Júnior2, Daniel Moreira Dos Santos2, Daiane Boff2, Vívian Louise Soares de Oliveira2, Karla Aparecida Guimarães Gusmão Gomes3, Rosana de Carvalho Cruz4, Patrícia Luciana de Oliveira4, Paula Prazeres Magalhães4, Patricia Silva Cisalpino4, Luiz de Macêdo Farias4, Elaine Maria de Souza-Fagundes5, Johannes Delp6,7, Marcel Leist6, Jarbas Magalhães Resende3, Flávio Almeida Amaral2, Adriano Monteiro de Castro Pimenta2, Simone Odília Antunes Fernandes1, Valbert Nascimento Cardoso1, Maria Elena de Lima2,8.   

Abstract

In the continuing search for novel antibiotics, antimicrobial peptides are promising molecules, due to different mechanisms of action compared to classic antibiotics and to their selectivity for interaction with microorganism cells rather than with mammalian cells. Previously, our research group has isolated the antimicrobial peptide LyeTx I from the venom of the spider Lycosa erythrognatha. Here, we proposed to synthesize three novel shortened derivatives from LyeTx I (LyeTx I mn; LyeTx I mnΔK; LyeTx I mnΔKAc) and to evaluate their toxicity and biological activity as potential antimicrobial agents. Peptides were synthetized by Fmoc strategy and circular dichroism analysis was performed, showing that the three novel shortened derivatives may present membranolytic activity, like the original LyeTx I, once they folded as an alpha helix in 2.2.2-trifluorethanol and sodium dodecyl sulfate. In vitro assays revealed that the shortened derivative LyeTx I mnΔK presents the best score between antimicrobial (↓ MIC) and hemolytic (↑ EC50) activities among the synthetized shortened derivatives, and LUHMES cell-based NeuriTox test showed that it is less neurotoxic than the original LyeTx I (EC50 [LyeTx I mnΔK] ⋙ EC50 [LyeTx I]). In vivo data, obtained in a mouse model of septic arthritis induced by Staphylococcus aureus, showed that LyeTx I mnΔK is able to reduce infection, as demonstrated by bacterial recovery assay (∼10-fold reduction) and scintigraphic imaging (less technetium-99m labeled-Ceftizoxime uptake by infectious site). Infection reduction led to inflammatory process and pain decreases, as shown by immune cells recruitment reduction and threshold nociception increment, when compared to positive control group. Therefore, among the three shortened peptide derivatives, LyeTx I mnΔK is the best candidate as antimicrobial agent, due to its smaller amino acid sequence and toxicity, and its greater biological activity.

Entities:  

Keywords:  Antimicrobial peptide; LyeTx I mnΔK; infection; inflammation process; septic arthritis; shortened derivatives from LyeTx I

Mesh:

Substances:

Year:  2020        PMID: 33175610      PMCID: PMC7885047          DOI: 10.1177/1535370220966963

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  30 in total

Review 1.  How do neutrophils and pathogens interact?

Authors:  Anne Mayer-Scholl; Petra Averhoff; Arturo Zychlinsky
Journal:  Curr Opin Microbiol       Date:  2004-02       Impact factor: 7.934

Review 2.  Nociception, pain, and antinociception: current concepts.

Authors:  W Riedel; G Neeck
Journal:  Z Rheumatol       Date:  2001-12       Impact factor: 1.372

Review 3.  Radiolabelled antimicrobial peptides for infection detection.

Authors:  Antonella Lupetti; Mick M Welling; Ernest K J Pauwels; Peter H Nibbering
Journal:  Lancet Infect Dis       Date:  2003-04       Impact factor: 25.071

4.  Correlation of structural features of novel 1,2,3-triazoles with their neurotoxic and tumoricidal properties.

Authors:  Elaine Maria de Souza-Fagundes; Johannes Delp; PedroH D M Prazeres; Lucas Bonfim Marques; Arturene Maria Lino Carmo; Pedro Henrique Fazza Stroppa; Nicolas Glanzmann; Jaffar Kisitu; Dàvid Szamosvàri; Thomas Böttcher; Marcel Leist; Adilson David da Silva
Journal:  Chem Biol Interact       Date:  2018-06-23       Impact factor: 5.192

5.  Antibacterial Effect of Synthetic Peptide LyeTxI and LyeTxI/β-Cyclodextrin Association Compound Against Planktonic and Multispecies Biofilms of Periodontal Pathogens.

Authors:  Edison Andrés Cruz Olivo; Daniel Santos; Maria Elena de Lima; Vera Lúcia Dos Santos; Rubén Dario Sinisterra; María Esperanza Cortés
Journal:  J Periodontol       Date:  2016-12-17       Impact factor: 6.993

6.  Crucial role of neutrophils in the development of mechanical inflammatory hypernociception.

Authors:  Thiago M Cunha; Waldiceu A Verri; Ieda R Schivo; Marcelo H Napimoga; Carlos A Parada; Stephen Poole; Mauro M Teixeira; Sergio H Ferreira; Fernando Q Cunha
Journal:  J Leukoc Biol       Date:  2008-01-18       Impact factor: 4.962

Review 7.  High-quality 3D structures shine light on antibacterial, anti-biofilm and antiviral activities of human cathelicidin LL-37 and its fragments.

Authors:  Guangshun Wang; Biswajit Mishra; Raquel F Epand; Richard M Epand
Journal:  Biochim Biophys Acta       Date:  2014-01-23

8.  LyeTx I, a potent antimicrobial peptide from the venom of the spider Lycosa erythrognatha.

Authors:  D M Santos; R M Verly; D Piló-Veloso; M de Maria; M A R de Carvalho; P S Cisalpino; B M Soares; C G Diniz; L M Farias; D F F Moreira; F Frézard; M P Bemquerer; A M C Pimenta; M E de Lima
Journal:  Amino Acids       Date:  2009-11-28       Impact factor: 3.520

Review 9.  Mechanisms and consequences of bacterial resistance to antimicrobial peptides.

Authors:  D I Andersson; D Hughes; J Z Kubicek-Sutherland
Journal:  Drug Resist Updat       Date:  2016-04-20       Impact factor: 18.500

10.  Antimicrobial peptides.

Authors:  Ling-Juan Zhang; Richard L Gallo
Journal:  Curr Biol       Date:  2016-01-11       Impact factor: 10.834

View more
  1 in total

Review 1.  Antimicrobial Peptide Analogs From Scorpions: Modifications and Structure-Activity.

Authors:  Bruno Amorim-Carmo; Adriana M S Parente; Eden S Souza; Arnóbio A Silva-Junior; Renata M Araújo; Matheus F Fernandes-Pedrosa
Journal:  Front Mol Biosci       Date:  2022-05-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.